Core Technology

The engine behind MedMira’s world class rapid diagnostic solutions is our patented rapid flow-through technology (RFT) platform.  The RFT platform relies on highly specific antigen-antibody reactions for the detection of disease-specific biomarkers in human specimens.  A special membrane is coated with disease-specific antigens or antibodies to capture the corresponding biomarker in the specimen.  The simple test procedure involves adding the specimens to the test cartridge and allowing it to flow through the membrane.  If the specimen contains the target antibodies or antigens, they are captured on the test membrane and can be visually interpreted immediately after the addition of a detection reagent.  

Our technology platform is unique in its ability to detect multiple biomarkers specific to several diseases using a single cartridge.  Our Multiplo line of rapid tests for HIV, Hepatitis B and C use the platform’s advanced capabilities to deliver three test results using one test cartrige and one drop of specimen.  Alternatively, the platform can be used to semi-quantitatively detect up to three different levels of the same analyte.  MedMira’s multiple rapid tests stand alone as the only quality rapid tests in the world with this capability.

MedMira’s RFT platform has been proven time and again, with our line of rapid HIV tests earning “gold standard” regulatory approvals in major international markets including North America, Europe, and China.  The RFT platform is a highly versatile product engine, enabling MedMira’s R&D team to quickly move new rapid tests for infectious diseases, STDs, and chronic conditions through the discovery and development phases to commercialization.

Precision pipetting, sample manipulation, specialized equipment and training are not required to perform any of MedMira's rapid tests, making it an invaluable diagnostic resource in laboratory, point-of-care, and over-the counter testing.